1-8 of 8
David Ross, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

Veena Fauble, MD, Robyn M. Emanuel, MD, MPH, Holly Lynn Geyer, MD, Amylou Constance Dueck, PhD, Nicolaus Kroeger, MD, Bart L Scott, MD, Aaron T Gerds, MD, MS, Uday R Popat, MD, Sergio A Giralt, MD, Vikas Gupta, MD, FRCP, FRCPath, David Ross, MBBS, PhD, Emily Knight, Ana Kerguelen Fuentes, MD, Christen Lykkegaard Andersen, MD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD, PhD, Peter Johansson, MD, PhD, Bjorn Andreasson, MD, Federico Sackmann, Jean-Loup Demory, MD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, Jan J. Michiels, PhD, Deepti H Radia, MD FRCPath MSc Med Ed, Michael Boxer, MD, Ruben A. Mesa, MD
Journal: Blood
Blood (2013) 122 (21): 4090.
https://doi.org/10.1182/blood.V122.21.4090.4090
Published: 2013
Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2012) 120 (21): 165.
https://doi.org/10.1182/blood.V120.21.165.165
Published: 2012
Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2012) 120 (21): 3771.
https://doi.org/10.1182/blood.V120.21.3771.3771
Published: 2012
Journal Articles

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

Nisha Rao, Carolyn M Butcher, MMedSc(Hon), Petra J Neufing, Sarah Bray, Chris N Hahn, Hamish S Scott, PhD, Junia V. Melo, MD, PhD, David Ross, MBBS, PhD, Ian D Lewis, MBBS, PhD, Peter Bardy, MD, Richard J D'Andrea, PhD
Journal: Blood
Blood (2011) 118 (21): 2823.
https://doi.org/10.1182/blood.V118.21.2823.2823
Published: 2011
Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2011) 118 (21): 451.
https://doi.org/10.1182/blood.V118.21.451.451
Published: 2011
Journal Articles

Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance

Susan Branford, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Jodi Prime, BSc., David Ross, MBBS, PhD, Timothy P. Hughes, MD, MBBS
Journal: Blood
Blood (2011) 118 (21): 113.
https://doi.org/10.1182/blood.V118.21.113.113
Published: 2011
Journal Articles

Towards DNA-Based Monitoring of Therapy In Chronic Myeloid Leukemia

Alexander A. Morley, MD, FRACP, FRCPA, MB, BS, Paul Bartley, PhD, David Ross, MBBS, PhD, Sue Latham, BSc, Brad Budgen, B, Biotech, Susan Branford, PhD, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2010) 116 (21): 2284.
https://doi.org/10.1182/blood.V116.21.2284.2284
Published: 2010
Journal Articles

DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML).

Alexander Morley, MD, Paul Bartley, PhD, Henry Martin-Harris, BSc, Sue Latham, BSc, David Ross, MBBS, Timothy Hughes, MD
Journal: Blood
Blood (2007) 110 (11): 2946.
https://doi.org/10.1182/blood.V110.11.2946.2946
Published: 2007